Nothing Special   »   [go: up one dir, main page]

HK1149012A1 - Triazolium salts as par1 inhibitors, production thereof, and use as medicaments - Google Patents

Triazolium salts as par1 inhibitors, production thereof, and use as medicaments

Info

Publication number
HK1149012A1
HK1149012A1 HK11103241.8A HK11103241A HK1149012A1 HK 1149012 A1 HK1149012 A1 HK 1149012A1 HK 11103241 A HK11103241 A HK 11103241A HK 1149012 A1 HK1149012 A1 HK 1149012A1
Authority
HK
Hong Kong
Prior art keywords
medicaments
production
triazolium salts
par1 inhibitors
par1
Prior art date
Application number
HK11103241.8A
Other languages
English (en)
Inventor
Uwe Heinelt
Volkmar Wehner
Matthias Herrmann
Karl Schoenafinger
Henning Steinhagen
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1149012A1 publication Critical patent/HK1149012A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK11103241.8A 2008-02-05 2011-03-30 Triazolium salts as par1 inhibitors, production thereof, and use as medicaments HK1149012A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290114 2008-02-05
PCT/EP2009/000407 WO2009097971A1 (fr) 2008-02-05 2009-01-23 Sels de triazolium en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que médicaments

Publications (1)

Publication Number Publication Date
HK1149012A1 true HK1149012A1 (en) 2011-09-23

Family

ID=39816936

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11103241.8A HK1149012A1 (en) 2008-02-05 2011-03-30 Triazolium salts as par1 inhibitors, production thereof, and use as medicaments

Country Status (20)

Country Link
US (2) US8198272B2 (fr)
EP (1) EP2240486B1 (fr)
JP (1) JP5577259B2 (fr)
KR (1) KR20100120139A (fr)
CN (1) CN101981035B (fr)
AU (1) AU2009211888B2 (fr)
BR (1) BRPI0907487A2 (fr)
CA (1) CA2713551C (fr)
CO (1) CO6311103A2 (fr)
ES (1) ES2553588T3 (fr)
HK (1) HK1149012A1 (fr)
IL (1) IL207203A0 (fr)
MA (1) MA32062B1 (fr)
MX (1) MX2010007893A (fr)
MY (1) MY148732A (fr)
NZ (1) NZ587142A (fr)
PL (1) PL2240486T3 (fr)
RU (1) RU2494100C2 (fr)
WO (1) WO2009097971A1 (fr)
ZA (1) ZA201004468B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5526040B2 (ja) * 2008-02-05 2014-06-18 サノフイ Ｐａｒ１阻害剤としてのトリアゾロピリダジン類、その製造法および薬剤としての使用
US8673890B2 (en) 2009-10-29 2014-03-18 Janssen Pharmaceutica Nv 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist
CN102961382B (zh) * 2012-11-28 2014-07-16 玉林师范学院 一种骨肉瘤细胞抑制剂及制备方法
AR107165A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺
CN115385853B (zh) * 2022-10-17 2024-02-02 山东友道化学有限公司 一种2-肼基-3-氯吡啶的生产方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578464A (en) 1983-11-22 1986-03-25 Merrell Dow Pharmaceuticals Inc. 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds
LT3200B (en) * 1992-03-18 1995-03-27 Takeda Chemical Industries Ltd Triazolopyridazine methodfor production thereof and use
KR970706287A (ko) * 1994-09-16 1997-11-03 다께다 구니오 트리아졸로피리다진의 제조 방법, 그의 제조를 위한 중간체 및 약제로서의 그의 용도(triazolopyridazines process and intermediates for their preparation and their use as medicaments)
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
BR0208985A (pt) * 2001-04-19 2004-03-09 Eisai Co Ltd Derivados de 2-iminopirrolidina
EP1391452A4 (fr) 2001-05-25 2005-10-26 Mochida Pharm Co Ltd Derive de 4-hydroxypiperidine a activite analgesique
US6984653B2 (en) 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
PL214718B1 (pl) 2002-04-16 2013-09-30 Schering Corp Tricykliczny antagonista receptora trombinowego, zawierajaca go kompozycja farmaceutyczna i jego zastosowanie
CN100439336C (zh) 2003-02-19 2008-12-03 卫材R&D管理有限公司 制备环状苯甲脒衍生物的方法
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
WO2006051648A1 (fr) 2004-11-09 2006-05-18 Eisai R & D Management Co., Ltd. Médicament contenant un antagoniste du récepteur de la thrombine au titre de principe actif et destiné au traitement d'angiospasmes causés par une hémorragie sous-arachnoïdienne
DK1966214T3 (en) * 2005-12-21 2017-02-13 Janssen Pharmaceutica Nv TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS
DE102006025318A1 (de) 2006-05-31 2007-12-06 Bayer Healthcare Ag Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung
JP5526040B2 (ja) 2008-02-05 2014-06-18 サノフイ Ｐａｒ１阻害剤としてのトリアゾロピリダジン類、その製造法および薬剤としての使用
CA2713554C (fr) 2008-02-05 2016-09-06 Sanofi-Aventis Imidazopyridazines en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que medicaments
EP2242740B1 (fr) 2008-02-05 2012-12-12 Sanofi Dérivés de sf5 en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que médicaments
US8394823B2 (en) * 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
WO2009126624A1 (fr) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Composés triazolos utiles en tant qu'inhibiteurs de dgat1
JP2011528375A (ja) * 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト

Also Published As

Publication number Publication date
RU2494100C2 (ru) 2013-09-27
CA2713551A1 (fr) 2009-08-13
IL207203A0 (en) 2010-12-30
MA32062B1 (fr) 2011-02-01
MY148732A (en) 2013-05-31
JP2011511017A (ja) 2011-04-07
RU2010136941A (ru) 2012-03-20
CN101981035A (zh) 2011-02-23
US8198272B2 (en) 2012-06-12
NZ587142A (en) 2012-04-27
ES2553588T3 (es) 2015-12-10
US8853206B2 (en) 2014-10-07
CN101981035B (zh) 2013-08-28
EP2240486B1 (fr) 2015-09-09
EP2240486A1 (fr) 2010-10-20
PL2240486T3 (pl) 2016-02-29
MX2010007893A (es) 2010-08-09
WO2009097971A1 (fr) 2009-08-13
BRPI0907487A2 (pt) 2015-07-14
KR20100120139A (ko) 2010-11-12
JP5577259B2 (ja) 2014-08-20
CO6311103A2 (es) 2011-08-22
ZA201004468B (en) 2011-03-30
AU2009211888A1 (en) 2009-08-13
US20110034452A1 (en) 2011-02-10
CA2713551C (fr) 2016-06-14
US20120208805A1 (en) 2012-08-16
AU2009211888B2 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
IL254076B (en) 5-Fluoropyrimidinone derivatives, preparations containing them and methods of using them
PT2242740E (pt) Derivados de sf5 como inibidores do par1, sua preparação e utilização como produtos farmacêuticos
IL211115A0 (en) Novel benzamides, production thereof, and use thereof as medicaments
ZA201300957B (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and use thereof
IL212605A (en) Pyrimidine-4-carboxamide cycles and their use as drugs
ZA201001015B (en) (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
HK1167597A1 (en) Dodeca-2e,4e-diene amides and their use as medicaments and cosmetics -2e4e-
ZA201001014B (en) (Cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
PL2353403T3 (pl) Zastosowanie 1-(2,4-dihydroksy-fenylo)-3-(3-hydroksy-4-metoksy-fenylo)-propan-1-onu
PL2307391T3 (pl) Tiadiazolilooksyfenyloamidyny i ich zastosowanie jako środki grzybobójcze
PL2307390T3 (pl) Tiadiazolilooksyfenyloamidyny i ich zastosowanie jako środki grzybobójcze
IL212059A0 (en) Novel nitrogenous heterocyclic compounds, preparation thereof and use thereof as antibacterial medicaments
ZA201200890B (en) 5,6-bicylic heteroaryl-containing urea compounds as kinase inhibitors
IL211713A (en) History of Anilinopyrimidine Converted to Sulfoxaamine as CDK Inhibitors, Manufactured and Used as Drugs
IL215835A (en) Carboxamide compounds and their use as a drug
IL216388A0 (en) New compounds, pharmaceutical composition and methods relating thereto
HK1149012A1 (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
IL220586A (en) Carboxamide compound, a pharmaceutical composition containing it and its use
GB0803054D0 (en) Medicament
HK1148956A1 (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
HK1149011A1 (en) Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments
PT2603217E (pt) Novos derivados 6,7-dissubstituídos de isoquinolina e sua utilização
EP2363132A4 (fr) Utilisation de sophoricoside dans la préparation de médicaments
AP2788A (en) Simalikalactone E and use thereof as a medicament
PL391832A1 (pl) Sole N-triazynyloamoniowe, sposób ich wytwarzania oraz ich zastosowanie

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180123